Principal Investigator
Thomas Harrington
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20231127
Clinical Trial Summary
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
Phase
Phase II/III
Funding Agency/Sponsor
Industrial
Disease
Leukemia
Contact Information
Phone Number
305-243-2647